Premier Biomedical Inc (BIEI)

[squidster]

To your credit, you obviously know the U.S. patent system better than most and I have appreciated your insight regarding that. It would seem that your investment thesis is based around the CTLA-4 patent, that's cool but I would suggest that there are other facets to the biolgics division that could bring in outside interest as well. So it's not so obvious to me that there is no interest outside of the patent. So let's just agree to disagree...
In the meantime the pain management division seems to be gaining traction and if there is enough revenue there to keep from further dilution I am willing to sit tight for awhile longer